Cited by 678Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

Shigematsu, Hisayuki, Takahashi, Takao, Nomura, Masaharu, Majmudar, Kuntal, Suzuki, Makoto, Lee, Huei, Wistuba, Ignacio I., Fong, Kwun M., Toyooka, Shinichi, Shimizu, Nobuyoshi, Fujisawa, Takehiko, Minna, John D., Gazdar, Adi F.·2005·Cancer Research

DOI 10.1158/0008-5472.can-04-4235

Open this paper in CoChat — free account

Abstract

Mutations in the epidermal growth factor receptor gene (EGFR) in lung cancers predict for sensitivity to EGFR kinase inhibitors. HER2 (also known as NEU, EGFR2, or ERBB2) is a member of the EGFR family of receptor tyrosine kinases and plays important roles in the pathogenesis of certain human cancers, and mutations have recently been reported in lung cancers. We sequenced the tyrosine kinase domain of HER2 in 671 primary non-small cell lung cancers (NSCLC), 80 NSCLC cell lines, and 55 SCLCs and other neuroendocrine lung tumors as well as 85 other epithelial cancers (breast, bladder, prostate, and colorectal cancers) and compared the mutational status with clinicopathologic features and the presence of EGFR or KRAS mutations. HER2 mutations were present in 1.6% (11 of 671) of NSCLC and were absent in other types of cancers. Only one adenocarcinoma cell line (NCI-H1781) had a mutation. All HER2 mutations were in-frame insertions in exon 20 and target the identical corresponding region as did EGFR insertions. HER2 mutations were significantly more frequent in never smokers (3.2%, 8 of 248; P=0.02) and adenocarcinoma histology (2.8%, 11 of 394; P=0.003). In 394 adenocarcinoma cases, HER2 mutations preferentially targeted Oriental ethnicity (3.9%) compared with other ethnicities (0.7%), female gender (3.6%) compared with male gender (1.9%) and never smokers (4.1%) compared with smokers (1.4%). Mutations in EGFR, HER2, and KRAS genes were never present together in individual tumors and cell lines. The remarkable similarities of mutations in EGFR and HER2 genes involving tumor type and subtype, mutation type, gene location, and specific patient subpopulations targeted are unprecedented and suggest similar etiologic factors. EGFR, HER2, and KRAS mutations are mutually exclusive, suggesting different pathways to lung cancer in smokers and never smokers.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-04-4235

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Revisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · CHEST Journal · doi:10.1378/chest.111.6.1710 · Cited by 4,565
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Self-citation

Show all 28 references

Sorted by citations

Items 501–600 of 678

Hereditary Lung Cancer Risk: Recent Discoveries and Implications for Genetic Counseling and Testing
Koeller, D. R., Chen, R., & Oxnard, G. R. (2018) · Current Genetic Medicine Reports · doi:10.1007/s40142-018-0140-2 · Cited by 5
Pathology and Personalized Medicine in Lung Cancer
Kerr, K. M., Loo, P. S., & Nicolson, M. C. (2013) · Lung Cancer Management · doi:10.2217/lmt.12.53 · Cited by 5
Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status
de Sousa, V. M. L., Rodrigues, C., Silva, M. M. P., Alarcão, A., & Carvalho, L. (2015) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2014.09.009 · Cited by 5
The Presence of HER2 Exon 20 Insertion in Patients with Central Nervous System Metastases from Non-Small Lung Cancer—A Potential Application in Classification for Therapy
Nicoś, M., Krawczyk, P. A., Mlak, R., Sawicki, M., Jarosz, B., Powrózek, T., Milanowski, P., Trojanowski, T., & Milanowski, J. (2013) · Advances in respiratory medicine · doi:10.5603/arm.34788 · Cited by 5
Molecular Basis of Lung Carcinogenesis
Fong, K. M., Larsen, J. E., Wright, C. M., Sriram, K. B., Davidson, M. R., Daniels, M. G., Sekido, Y., Bowman, R., Yang, I. A., & Minna, J. D. (2016) · Springer eBooks · doi:10.1007/978-1-59745-458-2_28 · Cited by 5
Self-citation
New strategy for suppressing the growth of lung cancer cells harboring mutations in the ATP‐binding region of EGFR by targeting the molecular motor MYO1D
Ko, Y., Kang, H., Bae, J. A., Kim, S. J., Kim, N., Chung, I. J., Moon, K., Rho, J. K., Kim, H., Ha, H., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.515 · Cited by 5
Nouvelles cibles et nouvelles molécules en oncologie thoracique
Rouvière, D., Bousquet, E., Tostivint, E. P., Milia, J., Guibert, N. M., & Mazières, J. (2015) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2015.02.091 · Cited by 5
Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma
Watanabe, Y., Shiraishi, K., Takahashi, F., Yoshida, A., Suzuki, K., Asamura, H., Takeuchi, M., Furuta, K., & Tsuta, K. (2014) · Histopathology · doi:10.1111/his.12556 · Cited by 5
Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor
Jang, J., Son, J., Park, E., Kosaka, T., Saxon, J. A., Clercq, D. J. H. D., Choi, H. G., Tanizaki, J., Eck, M. J., Janne, P. A., et al. (2018) · Angewandte Chemie · doi:10.1002/ange.201805187 · Cited by 5
Republished: Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?
Ou, S. I. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2012-201296rep · Cited by 5
Emerging Targeted Therapies for HER2-Mutant NSCLC
Rio, B. D., Masini, S., Cáceres-Galvis, C., Torres-Jiménez, J., Bote, H., Berjaga, M. Z., Baena-, J., Serrano, C., Nuñez, J. A., Ponce-Aix, S., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103899 · Cited by 4
Dynamic characterization of circulating tumor DNA in HER2-altered advanced non-small cell lung cancer treated with pyrotinib and apatinib: Exploratory biomarker analysis from PATHER2 study
Dong, Y., Yang, G., Yang, Y., Zhang, S., Wang, Y., & Xu, H. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.108062 · Cited by 4
Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations
König, D., & Rothschild, S. I. (2020) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2020.05.019 · Cited by 4
Differences in Radiosensitivity According to EGFR Mutation Status in Non-Small Cell Lung Cancer: A Clinical and In Vitro Study
Tanaka, H., Karita, M., Ueda, K., Ono, T., Kajima, M., Manabe, Y., Fujimoto, K., Yuasa, Y., & Shiinoki, T. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm14010025 · Cited by 4
Trastuzumab-Resistance and Breast Cancer
Dokmanovic, M., & Jin, W. (2011) · InTech eBooks · doi:10.5772/20936 · Cited by 4
Implementation of modern therapy approaches and research for non‐small cell lung cancer in J apan
Nakanishi, Y. (2015) · Respirology · doi:10.1111/resp.12460 · Cited by 4
Le sevrage tabagique en oncologie thoracique
Ruppert, A.-M., Amrioui, F., Gounant, V., Wislez, M., Bouvier, F., & Cadranel, J. L. (2013) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2013.02.017 · Cited by 4
Tyrosine Kinase Inhibitors for EGFR Gene Mutation-Positive Non-SmallCell Lung Cancers: An Update for Recent Advances in Therapeutics
(2015) · Journal of Pharmacovigilance · doi:10.4172/2329-6887.1000155 · Cited by 4
Infrequent ERBB2 mutations in Chinese patients with non-small cell lung cancer.
Feng, S., Ling, H., Guo, H., Tong, L., Hu, G., Liao, L., Lv, X., Tan, H., & Wu, Y. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2014.03.20 · Cited by 4
Association between thyroid cancer and epidermal growth factor receptor mutation in female with nonsmall cell lung cancer
Na, I. I., Kim, S., Kim, H.-R., 김철현, Koh, J.-S., Baek, H., Choi, C.-M., Song, J., & Lee, J. (2017) · Annals of Thoracic Medicine · doi:10.4103/1817-1737.197774 · Cited by 4
A narrative review of ERBB2 in non-small cell lung carcinoma
Sharma, M., Dewan, A., Diwan, H., Nathany, S., & Batra, U. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_323_21 · Cited by 4
Quelle plateforme pour prendre en charge de façon personnalisée le cancer bronchique ?
Ruppert, A.-M., Antoine, M., Beau‐Faller, M., Cadranel, J. L., & Wislez, M. (2012) · Bulletin du Cancer · doi:10.1684/bdc.2012.1582 · Cited by 4
Biomarkers in Lung Cancer: Integration with Radiogenomics Data
Aréchaga-Ocampo, E., Villegas‐Sepúlveda, N., López–Urrutia, E., Ramos, M., López‐Camarillo, C., Pérez‐Plasencia, C., la Rosa, C. H. G.-D., Cortés‐González, C., & Luis, A. (2013) · InTech eBooks · doi:10.5772/53426 · Cited by 4
Actualités sur les thérapies ciblées dans les cancers bronchiques non à petites cellules, hors immunothérapie
Hamard, C., Ruppert, A.-M., Lavolé, A., Rozensztajn, N., Antoine, M., Cadranel, J. L., & Wislez, M. (2016) · Annales de Pathologie · doi:10.1016/j.annpat.2015.11.002 · Cited by 4
Basic science of lung cancer
Kristeleit, H., Enting, D., & Lai, R. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70186-1 · Cited by 4
Development of radiolabeled peptides to target p185HER2/neu receptors of cancer
Su, Z.-F. (2006) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.1137 · Cited by 4
Erlotinib as a Single Agent in Select Subsets of Patients with Advanced Non–Small-Cell Lung Cancer
Carrion, R. P., Gracián, A. C., & Hernández, P. (2007) · Clinical Lung Cancer · doi:10.3816/clc.2007.n.026 · Cited by 4
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR
Lecce, C. D., Eccher, S., Simbolo, M., Cocomazzi, A., Piredda, M. L., Caliò, A., Cima, L., Munari, E., Veronese, N., Avancini, A., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108594 · Cited by 3
Simultaneous detection of expression and gene mutations of HER2/neu in Chinese patients with gastric cancer
Zhang, X., Jian-Hui, Q., Sun, G., Yang, J., & Yang, Y. (2010) · Oncology Letters · doi:10.3892/ol_00000099 · Cited by 3
New Targets for Therapy in Lung Cancer
Mansfield, A. S., Dy, G. K., Ahn, M.-J., & Adjei, A. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00048-2 · Cited by 2
In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial
Hamada, A., Suda, K., Koga, T., Fujino, T., Nishino, M., Ohara, S., Chiba, M., Shimoji, M., Takemoto, T., Soh, J., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.10.014 · Cited by 3
A phase Ia study of a novel anti-HER2 antibody–drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors
Zhou, C., Wang, B., Teng, C. T., Yang, H., Piha-Paul, S. A., Richardson, G. E., Malalasekera, A., Sun, Y., Wang, W., Liu, J., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-05985-z · Cited by 3
[Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung Adenocarcinoma].
Li, P., Li, B., Shi, Y., Zhang, F., Shen, S., & Li, X. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.03.03 · Cited by 3
Mutations in epidermal growth factor receptor gene in esophageal squamous cell carcinoma patients in kashmir- a high incidence area of India.
Mir, R., Dar, N. A., Salam, I., & Shah, Z. A. (2008) · Europe PMC (PubMed Central) · Cited by 3
Theme: Oncology - Molecular Mechanisms Determining the Efficacy of EGF Receptor-specific Tyrosine Kinase Inhibitors help to Identify Biomarker Candidates
Yamauchi, M., & Gotoh, N. (2009) · Biomarkers in Medicine · doi:10.2217/bmm.09.9 · Cited by 3
Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors
Provencio, M., García‐Campelo, R., Isla, D., & de Castro, J. (2009) · Clinical & Translational Oncology · doi:10.1007/s12094-009-0381-3 · Cited by 3
Pathology of Lung Cancer
Wistuba, I. I., & Gazdar, A. F. (2006) · Springer eBooks · doi:10.1007/3-540-31040-1_8 · Cited by 3
Self-citation
Prise en charge thérapeutique des cancers bronchiques non à petites cellules métastatiques mutés pour l'EGFR
Cadranel, J. L., Ruppert, A.-M., Lavolé, A., Gounant, V., Beau‐Faller, M., & Wislez, M. (2012) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(12)70309-9 · Cited by 3
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
Chang, G., Lam, D. C.-L., Tsai, C., Chen, Y., Shih, J., Aggarwal, S., Wang, S., Kim, S., Kim, Y., Wahid, I., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01869-0 · Cited by 3
Molecular pathology
Laenger, F., Dickgreber, N. J., & Lehmann, U. (2015) · European Respiratory Society eBooks · doi:10.1183/2312508x.10009814 · Cited by 3
Favourable Prognostic Significance of HER2 Mutations in Canine Pulmonary Adenocarcinoma Following Surgical Resection
Ichimata, M., Kagawa, Y., Toshima, A., Igase, M., & Mizuno, T. (2025) · Veterinary and Comparative Oncology · doi:10.1111/vco.70020 · Cited by 2
A Comprehensive Analysis of HER2 status Heterogeneity Using Matched Samples among Potential Beneficiaries of Trastuzumab Deruxtecan Therapy in Non-Small Cell Lung Cancer
Wang, H., Sun, W., Wang, C., Yang, X., Chi, K., Liu, X., Huang, X., Zhou, L., & Lin, D. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.11.015 · Cited by 2
Evolving treatment strategies for HER2-altered non–small-cell lung cancer: the rise of TKIs and ADCs
Ballı, S., Başoğlu, T., & Ozdogan, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771869 · Cited by 2
“Omics” and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas
Tagliabue, E., & Campiglio, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00334 · Cited by 2
Adenocarcinoma
Kerr, K. M. (2012) · Molecular pathology library · doi:10.1007/978-1-4614-3197-8_13 · Cited by 2
Identification of Recurrent Insertions and Deletions in Exon 18 and 19 of Human Epidermal Growth Factor Receptor 2 as Potential Drivers in Non–Small-Cell Lung Cancer and Other Cancer Types
Yin, Y., Song, L., Shi, D., Liu, B., Li, X., Yang, M., Liu, B., Wang, D., & Qin, J. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00325 · Cited by 3
ERBB2 mutation landscape in non-small cell lung cancer patients in Northeast China
Li, H., Li, X., Lan, S., Zuo, X., Du, T., Liu, Y., Zhang, C., Zhu, J., & Cheng, Y. (2022) · Tumori Journal · doi:10.1177/03008916221101426 · Cited by 2
Biomarkers in Pulmonary Carcinomas
Gündoğdu, B., Gürel, D., & Ulukuş, E. Ç. (2022) · Springer eBooks · doi:10.1007/978-3-030-84432-5_5 · Cited by 2
Molecular Basis of Lung Cancer
Larsen, J. E., Govindan, R., & Minna, J. D. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00032-9 · Cited by 2
Self-citation
EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?
Finocchiaro, G., Toschi, L., Garassino, I. M. G., Vincenzo, F. D., Campagnoli, E., Zucali, P. A., Cavina, R., Ceresoli, G. L., Santoro, A., & Cappuzzo, F. (2007) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.1.2.183 · Cited by 2
Cancer therapies targeted to the epidermal growth factor receptor and its family members
Kane, S. E. (2006) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.16.2.147 · Cited by 2
[Advances on driver oncogenes of lung adenocarcinoma].
Wang, J., Zhang, Z., & Zhang, S. (2013) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2013.02.06 · Cited by 2
The use of biomarkers in the treatment of non-small cell lung cancer
Baumgart, M. A., & Pandya, K. J. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1136558 · Cited by 2
Pathology and Molecular Pathology of Lung Cancer
Chirieac, L. R., & Kobzik, L. (2016) · Springer eBooks · doi:10.1007/978-3-319-35153-7_20 · Cited by 2
Molecular Pathology of Lung Cancer
Corvalán, A. H., & Wistuba, I. I. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-524-8_1 · Cited by 2
Self-citation
Molecular Basis of Lung Cancer
Sato, M., Shames, D. S., Girard, L., Gazdar, A. F., & Minna, J. D. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10030-5 · Cited by 2
Self-citation
Mécanismes d’action des thérapeutiques ciblées… et mécanismes de résistance
Bergot, E., Richard, N., & Zalcman, G. (2007) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(07)78152-4 · Cited by 4
Lung cancer genetics and pharmacogenomics
Joshi, V. A., & Kucherlapati, R. (2006) · Cytogenetic and Genome Research · doi:10.1159/000095927 · Cited by 2
Combination of Standard Chemotherapy and Targeted Agents
Bareschino, M. A., Morgillo, F., & Ciardiello, F. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000268636.02709.b4 · Cited by 2
Telomerase activation in adenocarcinoma–bronchioloalveolar carcinoma
Brambilla, E. M., & Lantuéjoul, S. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00046606 · Cited by 2
Exploring the correlation between HER2 alterations and 18F-FDG PET/CT metabolic parameters and their prognostic value in EGFR-negative non-small-cell lung cancer patients
Ruan, M., Chang, C., Sun, J., Liu, L., Wang, L., Lei, B., Yan, H., Zhang, H., Xie, W., & Wang, Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05218-8 · Cited by 1
Immunotherapy as a later-line option for HER2 -altered advanced non-small-cell lung cancer: taxane might be a favorable partner
Yang, Y., Yang, G., Li, W., Xu, H., Hao, X., Zhang, S., Ai, X., Lei, S., & Wang, Y. (2023) · Future Oncology · doi:10.2217/fon-2022-0879 · Cited by 1
Prevalence and treatment of human epidermal growth factor receptor 2-altered non-small cell lung cancer: a retrospective analysis and systematic literature review
Yap, N. Y., Perumal, K., & Rajadurai, P. (2024) · ecancermedicalscience · doi:10.3332/ecancer.2024.1734 · Cited by 1
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies
Li, B. T., Gandhi, L., Ravichandran, V., Besse, B., Mazières, J., Shapiro, G. I., Boni, V., Waqar, S. N., Park, H., Quinn, D. I., et al. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.09.009 · Cited by 1
Genetically engineered ErbB2 overexpression sensitizes organoid-derived tumors to checkpoint inhibition in a syngeneic model of gastric cancer
He, J., Kirsche, L., Naščáková, Z., Manfredi, F., Magnani, C. F., Papa, G., Azizi, F., Leary, P., & Mueller, A. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012976 · Cited by 2
Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review
Goto, K., Hayashi, H., Maruti, S. S., Zettl, H., Mittal, L., Pathak, S., & Le, X. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01213-4 · Cited by 1
Recent advances in HER2-targeted inhibitors for cancer therapy
Zhu, W., & Lu, X. (2026) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2026.100127 · Cited by 1
[Role of HER2 in NSCLC].
Zhang, K., & Wang, H. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.10.08 · Cited by 1
Biologie moléculaire et prise en charge des patients atteints d’adénocarcinomes du poumon
Gibault, L., Cazes, A., Narjoz, C., & Blons, H. (2014) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2013.11.005 · Cited by 2
Genomic Applications in Pulmonary Malignancies
Büttner, R., Odenthal, M., & Merkelbach‐Bruse, S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0727-4_24 · Cited by 1
Fifth Educational Symposium of the Spanish Lung Cancer Group: Report on the Molecular Biology Workshop
Bover, I., Rolfo, C. D., Lewintre, E. J., Sirera, R., Camps, C., CHAIB-OUKADOUR, I., Ramírez, J. L., Benlloch, S., Molina‐Vila, M. Á., Simonetti, S., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.04.016 · Cited by 1
Expression and prognostic significance of the EGFR in solid tumors
Normanno, N., Bianco, C., Luca, A. D., Strizzi, L., Gallo, M., Mancino, M., & Salomon, D. S. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-356-1_16 · Cited by 1
Implications of Evolving Medical Science for Proof of Lung Cancer Causation
Frarey, L., & Martínez, J. S. (2015) · Beiträge zur Tabakforschung international · doi:10.1515/cttr-2015-0020 · Cited by 1
Rare molecular subsets among lung tumours - what makes them stand apart from the common?
Hasovits, C., & Pavlakis, N. (2015) · Cancer Forum · Cited by 1
Targeting Members of the Epidermal Growth Factor Receptor Family to Improve Response to Chemotherapy
O’Keefe, R. A., Grandis, J. R., & Johnson, D. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813753-6.00001-9 · Cited by 1
Le sevrage tabagique dans le cancer bronchique: les méthodes et les résultats; place de la e-cigarette
Ruppert, A.-M., & Urban, T. (2019) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(19)30084-9 · Cited by 1
Genomic Applications in Pulmonary Malignancies
Büttner, R., Heydt, C., & Merkelbach‐Bruse, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-96830-8_27 · Cited by 1
ERBB2 VARIANTS DISTRIBUTION IN NON-SMALL CELL LUNG CANCER: AN ITALIAN REAL-WORLD EXPERIENCE
Bessi, S., Malapelle, U., Pisapia, P., Pepe, F., Ottaviantonio, M., Troncone, G., & Biancalani, M. (2023) · Annals of Research in Oncology · doi:10.48286/aro.2023.67 · Cited by 1
Molecular Pathology of Lung Tumors
Lo, Y., & Lindeman, N. I. (2023) · Springer eBooks · doi:10.1007/978-3-031-35118-1_9 · Cited by 1
CT texture features of lung adenocarcinoma with HER2 mutation
Chen, W., Gao, P., Lu, F. Y., Wang, E., Liu, H., & Li, M. (2025) · BMC Cancer · doi:10.1186/s12885-025-13686-z · Cited by 1
A challenging case of enteric-type lung adenocarcinoma metastatic to the thyroid harboring RET-fusion diagnosed on fine-needle aspiration
Carillo, A. M., Luca, C. D., Nacchio, M., Salatiello, M., Pisapia, P., Damiano, V., Vigliar, E., D'Armiento, M. R., Troncone, G., & Bellevicine, C. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04093-7 · Cited by 1
Promising Response to Pyrotinib in Non-Small-Cell Lung Cancer with the Rare HER2 R456C Mutation: A Case Report
Wang, Y., Hu, J., Liu, R., Li, P., Wang, L., & Yang, G. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096371951250409093625 · Cited by 1
HER2 mutations in pulmonary adenocarcinoma presenting with ground-glass nodules
Yin, J., Huo, S., Chen, Z., Shi, Y., Sui, Q., Wang, Q., Xu, J., & Jiang, W. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03955-3 · Cited by 1
Épidémiologie du cancer bronchique : des considérations générales à l’aspect moléculaire
Mazières, J. (2014) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(14)70583-x · Cited by 1
Molecular Biology of Lung Cancer as the Basis for Targeted Therapy
Gautschi, O. P., Mack, P. C., Heighway, J., Gumerlock, P. H., & Gandara, D. R. (2007) · CRC Press eBooks · doi:10.3109/9781420020359.001 · Cited by 1
Genomics and Molecular Profiling of Lung Cancer
Xu, Z. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-396967-5.00012-8 · Cited by 1
Classification histomoléculaire des cancers pulmonaires
Antoine, M., Moroch, J., Kebir, F., Georges, M., Ruppert, A.-M., Wislez, M., & Cadranel, J. L. (2018) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(18)30016-8 · Cited by 1
Targeted Therapy in Non–Small-Cell Lung Cancer (Beyond Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase)
Dickinson, E., Zhao, D., & Reckamp, K. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55433-6.00009-2 · Cited by 1
Cancer bronchique et tabac : mise à jour
Sakhri, L., & Bertocchi, M. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2018.06.013 · Cited by 1
Cancer bronchique non à petites cellules avec anomalies moléculaires actionnables (KRAS, BRAF, MET, fusions)
Abdayem, P., & Planchard, D. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00107-5 · Cited by 1
Autres cibles addictives (KRAS, RET, HER2, NTRK…)
Simon, E., Abdayem, P., Planchard, D., & Greillier, L. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00120-3 · Cited by 1
Multiscale modeling of the ErbB receptor tyrosine kinase signaling network through theory and experiment
Telesco, S. (2011) · ScholarlyCommons (University of Pennsylvania) · Cited by 1
Molecular Biology of Preneoplastic Lesions of the Lung
Wistuba, I. I., & Gazdar, A. F. (2008) · Lung Cancer · doi:10.1002/9780470696330.ch5 · Cited by 1
Self-citation
[The biologic characteristics and treatment of non-small cell lung cancer in non smokers.].
Qiao, R., & Han, B. (2009) · PubMed · doi:10.3779/j.issn.1009-3419.2009.02.11 · Cited by 1
Clinical Application of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors against Non-Small Cell Lung Cancer
Chen, Y. (2005) · Cited by 1
Identification of frequent activating HER2 mutations in primary canine pulmonary adenocarcinomaPreprint
Lorch, G., Sivaprakasam, K., Zismann, V., Perdigones, N., Contente‐Cuomo, T., Nazareno, A., Facista, S. J., Wong, S., Drenner, K., Liang, W. S., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/528182 · Cited by 1
Combined use of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) as target therapy in non-small cell lung cancer (NSCLC)
Cretella, D. (2015) · DSpaceUnipr (University of Parma)
Cellular sensitivity to EGF receptor inhibitors
Thomson, S., Haley, J. D., & Yauch, R. L. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-356-1_22
Targeting the Phosphoinositide‐3‐kinase/Akt/Mammalian Target of Rapamycin Pathway
Granville, C. A., Memmott, R. M., Gills, J. J., & Dennis, P. A. (2006) · Wiley eBooks · doi:10.1002/9783527619665.ch38
Receptor Tyrosine Kinases
Matthews, D. J., & Gerritsen, M. E. (2010) · Wiley eBooks · doi:10.1002/9780470555293.ch3

Authors: Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., Fujisawa, T., Minna, J. D., & Gazdar, A. F.
Affiliations: Okayama University (JP)
1Hamon Center for Therapeutic Oncology Research, Departments of
Chiba University (JP)
Chung Shan Medical University (TW)
The University of Texas MD Anderson Cancer Center (US)
Prince Charles Hospital (AU)
The University of Texas Southwestern Medical Center (US)
ORCID: Majmudar, Kuntal
Suzuki, Makoto
Wistuba, Ignacio I.
Fong, Kwun M.
Toyooka, Shinichi
Minna, John D.
Gazdar, Adi F.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2005-03-01
Volume: 65
Issue: 5
Pages: 1642-1646
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-04-4235
OpenAlex: W2133867160
Cited by: 678
References: 28
Citations by year: 2026: 8 · 2025: 17 · 2024: 13 · 2023: 18 · 2022: 16 · 2021: 36 · 2020: 29 · 2019: 27 · 2018: 36 · 2017: 23 · 2016: 27 · 2015: 46 · 2014: 46 · 2013: 54 · 2012: 34
FWCI: 42.08
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute ((P50-CA70907, P50CA070907, 5U01 CA 8497102)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: HER2 mutation, lung adenocarcinoma, non-small cell lung cancer, EGFR mutation, KRAS mutation, tyrosine kinase domain, never smokers, ethnic differences in mutation frequency, lung cancer etiology, EGFR kinase inhibitors
MeSH terms: Adenocarcinoma, Aged, Aged, 80 and over, Amino Acid Sequence, Female, Humans, Lung Neoplasms, Male, Middle Aged, Molecular Sequence Data, Mutation, Neoplasms, Glandular and Epithelial, Genes, ras, Sequence Homology, Amino Acid, Genes, erbB-2, Genes, erbB-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks